Table 2. CGP test patient characteristics (n = 620).
| Tumor type tested | Total |
|---|---|
| Lung | 187 (30.2) |
| Sarcoma | 81 (13.1) |
| Colorectal | 64 (10.3) |
| Melanoma | 48 (07.7) |
| Ovarian | 43 (07.7) |
| Prostate | 31 (05.0) |
| Breast | 29 (04.7) |
| Uterine | 20 (03.2) |
| Neuroendocrine | 15 (02.4) |
| Brain/CNS | 14 (02.3) |
| Esophageal | 13 (02.1) |
| Kidney | 10 (01.6) |
| Pancreas | 8 (01.3) |
| Other Solid Tumor | 57 (09.2) |
| Tumor stage at the time of test order (number, %) | |
| Not Applicable | 6 (01.0) |
| I | 8 (01.3) |
| II | 14 (02.3) |
| III | 52 (08.4) |
| IV | 473 (76.3) |
| Unknown | 67 (10.8) |
| Prior treatment (number, %) | |
| None | 139 (22.4) |
| Chemotherapy/other standard of care | 381 (61.5) |
| Targeted Therapy (variant directed) | 16 (02.6) |
| Immunotherapy (checkpoint blockade) | 27 (04.4) |
| Clinical trial | 16 (02.6) |
| Unspecified | 70 (11.3) |
| Unknown | 21 (03.4) |
| Number of prior treatment regimens (number, %) | |
| 0 | 139 (22.4) |
| 1–2 | 198 (31.9) |
| 3–5 | 133 (21.5) |
| >5 | 59 (09.5) |
| Unspecified | 70 (11.3) |
| Unknown | 21 (03.4) |
| On drug at the time of test order (number, %) | 275 (44.4) |
| Turnaround time from specimen receipt (avg. days) | 8.2 |
| Most actionable variant level of evidence per test | |
| Level 1 (companion diagnostic) | 95 (15.3) |
| Level 2 (practice guidelines) | 81 (13.1) |
| Level 3 (off-label/clinical trials) | 361 (58.2) |
| Variants of unknown significance | 49 (07.9) |
| No variants detected | 34 (05.5) |
| Deceased (as of September 2018) | 318 (51.3) |
Unspecified = medical records indicated approximately when patient was last treated but electronic data lacked specific regimen details.
Unknown = medical records did not indicate whether or not patient was previously treated.